Literature DB >> 9420197

Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.

M P McCarthy1, W I White, F Palmer-Hill, S Koenig, J A Suzich.   

Abstract

The human papillomavirus (HPV) capsid is primarily composed of a structural protein denoted L1, which forms both pentameric capsomeres and capsids composed of 72 capsomeres. The L1 protein alone is capable of self-assembly in vivo into capsidlike structures referred to as viruslike particles (VLPs). We have determined conditions for the quantitative disassembly of purified HPV-11 L1 VLPs to the level of capsomeres, demonstrating that disulfide bonds alone are essential to maintaining long-term HPV-11 L1 VLP structure at physiological ionic strength. The ionic strength of the disassembly reaction was also important, as increased NaCl concentrations inhibited disassembly. Conversely, chelation of cations had no effect on disassembly. Quantitative reassembly to a homogeneous population of 55-nm, 150S VLPs was reliably achieved by the re-formation of disulfide linkages following removal of reducing agent at near-neutral pH and moderate NaCl concentration. HPV-11 L1 VLPs could also be dissociated by treatment with carbonate buffer at pH 9.6, but VLPs could not be regenerated following carbonate treatment. When probed with conformationally sensitive and/or neutralizing monoclonal antibodies, both capsomeres generated by disulfide reduction of purified VLPs and reassembled VLPs formed from capsomeres upon removal of reducing agents exhibited epitopes found on the surface of authentic HPV-11 virions. Antisera raised against either purified VLP starting material or reassembled VLPs similarly neutralized infectious HPV-11 virions. The ability to disassemble and reassemble VLPs in vitro and in bulk allows basic features of capsid assembly to be studied and also opens the possibility of packaging selected exogenous compounds within the reassembled VLPs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420197      PMCID: PMC109346     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Conserved features in papillomavirus and polyomavirus capsids.

Authors:  D M Belnap; N H Olson; N M Cladel; W W Newcomb; J C Brown; J W Kreider; N D Christensen; T S Baker
Journal:  J Mol Biol       Date:  1996-06-07       Impact factor: 5.469

2.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

3.  Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells.

Authors:  C Volpers; P Schirmacher; R E Streeck; M Sapp
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

4.  Local rule-based theory of virus shell assembly.

Authors:  B Berger; P W Shor; L Tucker-Kellogg; J King
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

5.  Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids.

Authors:  M E Hagensee; N H Olson; T S Baker; D A Galloway
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.

Authors:  T Sasagawa; P Pushko; G Steers; S E Gschmeissner; M A Hajibagheri; J Finch; L Crawford; M Tommasino
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

9.  Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae.

Authors:  K J Hofmann; J C Cook; J G Joyce; D R Brown; L D Schultz; H A George; M Rosolowsky; K H Fife; K U Jansen
Journal:  Virology       Date:  1995-06-01       Impact factor: 3.616

10.  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

Authors:  N D Christensen; R Höpfl; S L DiAngelo; N M Cladel; S D Patrick; P A Welsh; L R Budgeon; C A Reed; J W Kreider
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

View more
  44 in total

1.  Diffusion of macromolecules and virus-like particles in human cervical mucus.

Authors:  S S Olmsted; J L Padgett; A I Yudin; K J Whaley; T R Moench; R A Cone
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

2.  Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

3.  BUD22 affects Ty1 retrotransposition and ribosome biogenesis in Saccharomyces cerevisiae.

Authors:  Arun Dakshinamurthy; Katherine M Nyswaner; Philip J Farabaugh; David J Garfinkel
Journal:  Genetics       Date:  2010-05-24       Impact factor: 4.562

4.  Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells.

Authors:  Karina Araujo Aires; Aurora Marques Cianciarullo; Sylvia Mendes Carneiro; Luisa Lina Villa; Enrique Boccardo; Gaspar Pérez-Martinez; Isabel Perez-Arellano; Maria Leonor Sarno Oliveira; Paulo Lee Ho
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

5.  Underlying assumptions of developmental models.

Authors:  R J Britten
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

6.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

7.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines.

Authors:  M Sapp; C Fligge; I Petzak; J R Harris; R E Streeck
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

Authors:  Holly J Corbett; Germain J P Fernando; Xianfeng Chen; Ian H Frazer; Mark A F Kendall
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.